Tandem Diabetes Care Inc (NASDAQ:TNDM) has been given an average recommendation of “Hold” by the eight ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $11.83.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Saturday, January 6th. Robert W. Baird restated a “hold” rating and set a $3.00 target price on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Finally, Oppenheimer assumed coverage on Tandem Diabetes Care in a research report on Monday. They set a “buy” rating and a $6.00 target price for the company.
In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff acquired 750,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Twomey acquired 75,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was acquired at an average price of $2.00 per share, with a total value of $150,000.00. The disclosure for this purchase can be found here. 20.90% of the stock is currently owned by insiders.
Tandem Diabetes Care (NASDAQ TNDM) opened at $3.10 on Tuesday. The stock has a market capitalization of $127.84, a PE ratio of -0.16 and a beta of 0.44. Tandem Diabetes Care has a 12-month low of $2.14 and a 12-month high of $25.30. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.